Comparison of the Efficacy and Safety of Lindioil (Indigo Naturalis Oil Extract) Ointment to Protopic® (Tacrolimus 0.1%) Ointment in Treating Atopic Dermatitis: A Randomized, Evaluator-blind, Crossover, Active-Controlled Trial

Study start date: June 3, 2019

Inclusion Criteria: 1. Between 16 and 65 years old, female or male. 2. Chronic or sub-acute atopic dermatitis fulfilling the United Kingdom (UK) diagnostic criteria of atopic dermatitis. 3. Atopic dermatitis involving 3-40% of BSA at screening and baseline. 4. An IGA score of 2 (mild) to 4 (severe) at screening and baseline. 5. Not supposed to or unwilling to use corticosteroids. 6. Female patients of child-bearing age agree to use effective birth control measures approved by the investigator. 7. Agree to avoid natural and artificial sunlight over-exposure during the study. 8. Willing to comply with study protocol and agree to sign an informed consent form Exclusion Criteria: 1. Acute atopic dermatitis or concurrence of viral or bacterial infection on dermatitis lesion(s). 2. A history of topical or systematic hypersensitivity to indigo naturalis, tacrolimus, or the excipient(s) in the ointment(s). 3. Having received systemic therapy (e.g. immunosuppressive agents) within 14 days, or phototherapy (e.g. ultraviolet B (UVB), psoralen and ultraviolet A (PUVA)) within 42 days before the first application of the study medication. 4. Having used topical therapy (e.g. corticosteroids) for dermatitis within 4 days before the first application of the study medication. 5. Having a significant concurrent disease such as severe uncontrolled chronic disease (e.g., hypertension, diabetes mellitus, metabolic arthritis, hyperthyroidism), psychiatric disease, cancer or AIDS. 6. Having significant abnormal liver or renal function (Aspartate aminotransferase (AST)/ Alanine aminotransferase (ALT) \>3 x upper limit of normal (ULN), creatinine \>2.0 mg/dl) or clinically significant abnormal hematological lab result, according to investigator's judgment, on the safety lab test to be performed within 30 days before the baseline visit. 7. Women who are lactating, pregnant or planning to be pregnant during the study.